Pregnancy rate and ovarian hyperstimulation after luteal human chorionic gonadotropin in in vitro fertilization stimulated with gonadotropin-releasing hormone analog and menotropins
- PMID: 2104811
- DOI: 10.1016/s0015-0282(16)53222-1
Pregnancy rate and ovarian hyperstimulation after luteal human chorionic gonadotropin in in vitro fertilization stimulated with gonadotropin-releasing hormone analog and menotropins
Abstract
The value of luteal phase supplementation with human chorionic gonadotropin (hCG) was assessed after a combined protocol of ovarian stimulation, using a long acting gonadotropin releasing hormone analog (GnRH-a) and human menopausal gonadotropins (hMG), in a randomized prospective study of 36 consecutive cycles in an in vitro fertilization (IVF) program. The patients were allocated on the transfer day to either luteal phase supplementation with hCG (Group A, n = 18) or none (Group B, n = 18). Nine patients of Group A conceived as compared with 3 in Group B. Five patients, all in Group A, developed ovarian hyperstimulation syndrome (OHSS) (3 moderate and 2 severe forms). Analysis of the hormonal profiles disclosed similar progesterone (P), estradiol (E2), and E2/P ratio up to the 6th post ovum pick-up day. Then, E2 and mainly P levels decreased only in Group B resulting in a rising E2/P ratio. These findings stress the importance of luteal support in IVF cycles treated with GnRH-a. In light of the increased risk of OHSS among hCG treated patients, further studies are needed to assess the optimal preparation needed.
Similar articles
-
Luteinizing response to human chorionic gonadotropin does not predict outcome in gonadotropin releasing hormone agonist-suppressed/human menopausal gonadotropin-stimulated in vitro fertilization (IVF) cycles.J Assist Reprod Genet. 1992 Jun;9(3):244-7. doi: 10.1007/BF01203821. J Assist Reprod Genet. 1992. PMID: 1525454
-
Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention.Fertil Steril. 1990 Mar;53(3):502-9. doi: 10.1016/s0015-0282(16)53348-2. Fertil Steril. 1990. PMID: 2106456
-
Ovarian hyperstimulation syndrome following D-Trp-6 luteinizing hormone-releasing hormone microcapsules and menotropin for in vitro fertilization.Fertil Steril. 1988 Dec;50(6):912-6. doi: 10.1016/s0015-0282(16)60371-0. Fertil Steril. 1988. PMID: 2974429
-
The prevention of ovarian hyperstimulation syndrome.J Obstet Gynaecol Can. 2014 Nov;36(11):1024-1033. doi: 10.1016/S1701-2163(15)30417-5. J Obstet Gynaecol Can. 2014. PMID: 25574681 Review. English, French.
-
Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures.Hum Reprod. 1992 Mar;7(3):320-7. doi: 10.1093/oxfordjournals.humrep.a137642. Hum Reprod. 1992. PMID: 1587936 Review.
Cited by
-
The pathogenesis of ovarian hyperstimulation syndrome: a continuing enigma.J Assist Reprod Genet. 1998 Apr;15(4):202-9. doi: 10.1023/a:1023052419627. J Assist Reprod Genet. 1998. PMID: 9565850 Free PMC article. Review.
-
Elective cryopreservation of all embryos in women at risk of developing ovarian hyperstimulation syndrome may not prevent the condition but reduces the live birth rate.J Assist Reprod Genet. 1996 May;13(5):401-6. doi: 10.1007/BF02066172. J Assist Reprod Genet. 1996. PMID: 8739056 Clinical Trial.
-
The significance of 17 beta-estradiol levels in highly responding women during ovulation induction in IVF treatment: its impact and prognostic value with respect to oocyte maturation and treatment outcome.J Assist Reprod Genet. 1993 Apr;10(3):213-5. doi: 10.1007/BF01239223. J Assist Reprod Genet. 1993. PMID: 8400733 No abstract available.
-
Luteal phase support for assisted reproduction cycles.Cochrane Database Syst Rev. 2015 Jul 7;2015(7):CD009154. doi: 10.1002/14651858.CD009154.pub3. Cochrane Database Syst Rev. 2015. PMID: 26148507 Free PMC article.
-
A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program.J Endocrinol Invest. 1995 Jan;18(1):51-6. doi: 10.1007/BF03349699. J Endocrinol Invest. 1995. PMID: 7759785 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical